Oxidative modifications as triggers of AMD pathology

Studies on Retinal and Choroidal Disorders

Volumn , Issue , 2012, Pages 65-84

  Crabb, John W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885073563     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-606-7_3     Document Type: Chapter

References (124)

1. Jager R, Mieler W, Miller J (2008) Age-related macular degeneration. N Engl J Med 358(24):2606-2617.
2. Ding X, Patel M, Chan CC (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28(1):1-18.
3. Ferris FL III, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102(11):1640-1642.
4. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122(4):598-614.
5. Friedman D, O'Colmain B, Muñoz B, Tomany S, McCarty C, de Jong P, Nemesure B, Mitchell P, Kempen J, Group EDPR (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564-572.
6. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Bowes Rickman C, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration:hypothesis re-visited. Prog Retin Eye Res 29:95-112.
7. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 99(23):14682-14687.
8. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20(6):705-732.
9. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH (2000) A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 70(4):441-449.
10. Edwards A, Ritter R, Abel K, Manning A, Panhuysen C, Farrer L (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308(5720):421-424.
11. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102(20):7227-7232.
12. Haines J, Hauser M, Schmidt S, Scott W, Olson L, Gallins P, Spencer K, Kwan S, Noureddine M, Gilbert J, Schnetz-Boutaud N, Agarwal A, Postel E, Pericak-Vance M (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720):419-421.
13. Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C, Henning A, SanGiovanni J, Mane S, Mayne S, Bracken M, Ferris F, Ott J, Barnstable C, Hoh J (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385-389.
14. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Hageman GS, Dean M, Allikmets R, Group AGCS (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38(4):458-462.
15. Yates J, Sepp T, Matharu B, Khan J, Thurlby D, Shahid H, Clayton D, Hayward C, Morgan J, Wright A, Armbrecht A, Dhillon B, Deary I, Redmond E, Bird A, Moore A, Group GFiAS (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357(6):553-561.
16. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM (2007) Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 39(10):1200-1201.
17. Yuan X, Gu X, Crabb JS, Yue X, Shadrach K, Hollyfield JG, Crabb JW (2010) Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics 9(6):1031-1046.
18. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, Kleinman ME, Ponicsan SL, Hauswirth WW, Chiodo VA, Kariko K, Yoo JW, Lee DK, Hadziahmetovic M, Song Y, Misra S, Chaudhuri G, Buaas FW, Braun RE, Hinton DR, Zhang Q, Grossniklaus HE, Provis JM, Madigan MC, Milam AH, Justice NL, Albuquerque RJ, Blandford AD, Bogdanovich S, Hirano Y, Witta J, Fuchs E, Littman DR, Ambati BK, Rudin CM, Chong MM, Provost P, Kugel JF, Goodrich JA, Dunaief JL, Baffi JZ, Ambati J (2011) DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471(7338):325-330.
19. Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45(2):115-134.
20. Seddon JM, Willett WC, Speizer FE, Hankinson SE (1996) A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276(14):1141-1146.
21. AREDS (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417-1436.
22. Verhasselt V, Goldman M, Willems F (1998) Oxidative stress up-regulates IL-8 and TNFalpha synthesis by human dendritic cells. Eur J Immunol 28(11):3886-3890.
23. Matsue H, Edelbaum D, Shalhevet D, Mizumoto N, Yang C, Mummert ME, Oeda J, Masayasu H, Takashima A (2003) Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 171(6):3010-3018.
24. Hagenow K, Gelderman KA, Hultqvist M, Merky P, Backlund J, Frey O, Kamradt T, Holmdahl R (2009) Ncf1-associated reduced oxidative burst promotes IL-33R+T cell-mediated adjuvant-free arthritis in mice. J Immunol 183(2):874-881.
25. Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292(1):R18-R36.
26. Mendoza-Nunez VM, Ruiz-Ramos M, Sanchez-Rodriguez MA, Retana-Ugalde R, Munoz-Sanchez JL (2007) Aging-related oxidative stress in healthy humans. Tohoku J Exp Med 213(3):261-268.
27. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG (2003) Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 278(43):42027-42035.
28. Crabb JW, O'Neil J, Miyagi M, West K, Hoff HF (2002) Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci 11(4):831-840.
29. Ishibashi T, Murata T, Hangai M, Nagai R, Horiuchi S, Lopez PF, Hinton DR, Ryan SJ (1998) Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol 116(12):1629-1632.
30. Chio KS, Reiss U, Fletcher B, Tappel AL (1969) Peroxidation of subcellular organelles:formation of lipofuscinlike fluorescent pigments. Science 166(3912):1535-1536.
31. Ng KP, Gugiu B, Renganathan K, Davies MW, Gu X, Crabb JS, Kim SR, Rozanowska MB, Bonilha VL, Rayborn ME, Salomon RG, Sparrow JR, Boulton ME, Hollyfield JG, Crabb JW (2008) Retinal pigment epithelium lipofuscin proteomics. Mol Cell Proteomics 7(7):1397-1405.
32. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, Miyata T, Hjelmeland LM (1999) Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 40(3):775-779.
33. Hammes HP, Hoerauf H, Alt A, Schleicher E, Clausen JT, Bretzel RG, Laqua H (1999) N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 40(8):1855-1859.
34. Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland LM, Handa JT (1999) Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Mol Vis 5:11.
35. Howes KA, Liu Y, Dunaief JL, Milam A, Frederick JM, Marks A, Baehr W (2004) Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 45(10):3713-3720.
36. Glenn JV, Mahaffy H, Wu K, Smith G, Nagai R, Simpson DA, Boulton ME, Stitt AW (2009) Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to agerelated RPE dysfunction. Invest Ophthalmol Vis Sci 50(1):441-451.
37. Glenn JV, Beattie JR, Barrett L, Frizzell N, Thorpe SR, Boulton ME, McGarvey JJ, Stitt AW (2007) Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J 21(13):3542-3552.
38. Baynes JW (2001) The role of AGEs in aging: causation or correlation. Exp Gerontol 36(9):1527-1537.
39. Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93(4):1143-1152.
40. Ahmed KA, Muniandy S, Ismail IS (2007) Role of N-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 41(2):97-105.
41. Riviere S, Birlouez-Aragon I, Vellas B (1998) Plasma protein glycation in Alzheimer's disease. Glycoconj J 15(10):1039-1042.
42. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM (2008) Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 118(1):183-194.
43. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA (2008) Receptor for advanced glycation end products (RAGE) defi- ciency attenuates the development of atherosclerosis in diabetes. Diabetes 57(9):2461-2469.
44. Ni J, Yuan X, Gu J, Yue X, Gu X, Nagaraj RH, Crabb JW, The Clinical Genomic and Proteomic AMD Study Group (2009) Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics 8:1921-1933.
45. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tor M, Billiar T (2007) The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220:60-81.
46. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM (2007) Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 82(2):204-212.
47. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT (2009) RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7:17.
48. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108(7):949-955.
49. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106(5):842-853.
50. Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 86(3):505-512.
51. Ida H, Ishibashi K, Reiser K, Hjelmeland LM, Handa JT (2004) Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. Invest Ophthalmol Vis Sci 45(7):2348-2354.
52. Tian J, Ishibashi K, Reiser K, Grebe R, Biswal S, Gehlbach P, Handa JT (2005) Advanced glycation endproduct-induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response. Proc Natl Acad Sci USA 102(33):11846-11851.
53. Yamada Y, Ishibashi K, Bhutto IA, Tian J, Lutty GA, Handa JT (2006) The expression of advanced glycation endproduct receptors in RPE cells associated with basal deposits in human maculas. Exp Eye Res 82(5):840-848.
54. Jang G-F, Crabb AM, Zhang L, Crabb JW (2010) Improved methods for quantifying plasma protein advanced glycation end products as biomarkers for age-related macular degeneration. Invest Ophthalmol Vis Sci 51:E-Abstract 4113.
55. Crabb JW (2011) Proteomic biomarkers for age-related macular degeneration. Invest Ophthalmol Vis Sci 51:E-Abstract 855.
56. Hirata C, Nakano K, Nakamura N, Kitagawa Y, Shigeta H, Hasegawa G, Ogata M, Ikeda T, Sawa H, Nakamura K, Ienaga K, Obayashi H, Kondo M (1997) Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun 236(3):712-715.
57. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276(47):43836-43841.
58. Urata Y, Yamaguchi M, Higashiyama Y, Ihara Y, Goto S, Kuwano M, Horiuchi S, Sumikawa K, Kondo T (2002) Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic Biol Med 32(8):688-701.
59. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P (2002) Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 240(12):996-1002.
60. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101(6):1219-1224.
61. Okamoto T, Tanaka S, Stan AC, Koike T, Kase M, Makita Z, Sawa H, Nagashima K (2002) Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 63(2):186-195.
62. Schutt F, Bergmann M, Holz FG, Kopitz J (2003) Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci 44(8):3663-3668.
63. Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA (2007) Oxidative damage in age-related macular degeneration. Histol Histopathol 22(12):1301-1308.
64. Wang L, Clark M, Crossman D, Kojima K, Messinger J, Mobley J, Curcio C (2010) Abundant lipid and protein components of drusen. PLoS One 5(4):e10329.
65. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11(1):81-128.
66. Gu X, Sun M, Gugiu B, Hazen S, Crabb JW, Salomon RG (2003) Oxidatively truncated docosahexaenoate phospholipids: total synthesis, generation, and peptide adduction chemistry. J Org Chem 68(10):3749-3761.
67. Fliesler SJ, Anderson RE (1983) Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22(2):79-131.
68. Alvarez R, Aguirre G, Acland G, Anderson R (1994) Docosapentaenoic acid is converted to docosahexaenoic acid in the retinas of normal and prcd-affected miniature poodle dogs. Invest Ophthalmol Vis Sci 35:402-408.
69. Wang N, Anderson RE (1992) Enrichment of polyunsaturated fatty acids from rat retinal pigment epithelium to rod outer segments. Curr Eye Res 11(8):783-791.
70. Crabb JW, Gu X, Yan L, Rohde DE, West KA, Kamei M, Rayborn ME, Hollyfield JG, Salomon RG (2000) Oxidative protein modification in AMD from docosahexaenoic acid. Invest Ophthalmol Vis Sci S399:Abstract 2109.
71. Renganathan K, Gu J, Gugiu B, Gu X, Darrow R, Lewis H, Salomon RG, Organisciak DT, Crabb JW, Group CAS (2005) Similarities in plasma oxidative modifications from retinal light damage and AMD. Invest Ophthalmol Vis Sci 46:E-Abstract 3010.
72. Gu J, Paeur GJ, Yue X, Narendra U, Sturgill GM, Bena J, Gu X, Peachey NS, Salomon RG, Hagstrom SA, Crabb JW, Clinical Genomic and Proteomic AMD Study Group (2009) Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics 8:1338-1349.
73. Renganathan K, Sun M, Darrow R, Shan L, Gu X, Salomon RG, Hazen S, Organisciak D, Crabb JW (2003) Light induced protein modifications and lipid oxidation products in rat retina. Invest Ophthalmol Vis Sci 44:E-Abstract 5129.
74. Sun M, Finnemann SC, Febbraio M, Shan L, Annangudi SP, Podrez EA, Hoppe G, Darrow R, Organisciak DT, Salomon RG, Silverstein RL, Hazen SL (2006) Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: a potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J Biol Chem 281(7):4222-4230.
75. Renganathan K, Collier R, Gu X, Salomon RG, Kapin M, Hollyfield JG, Crabb JW (2004) Similarities in oxidative damage from AMD and retinal light damage. Invest Ophthalmol Vis Sci 45:Abstract 1795.
76. Gu X, Renganathan K, Grimm C, Wenzel A, Salomon RG, Reme CE, Crabb JW (2004) Rapid changes in retinal oxidative protein modifications induced by blue light. Invest Ophthalmol Vis Sci 45:E-Abstract 3474.
77. Miyagi M, Sakaguchi H, Darrow RM, Yan L, West KA, Aulak KS, Stuehr DJ, Hollyfield JG, Organisciak DT, Crabb JW (2002) Evidence that light modulates protein nitration in rat retina. Mol Cell Proteomics 1(4):293-303.
78. Gu J, Zhan X, Crabb JS, Bala E, Renganathan K, Hagstrom SA, Lewis H, Salomon RG, Crabb JW (2007) Oxidative modifications as biomarkers for AMD. Invest Ophthalmol Vis Sci 48:E-Abstract 34.
79. Renganathan K, Gu J, Collier R, Romano C, Salomon RG, Rayborn M, Hollyfield JG, Crabb JW (2009) Drugs that prevent retinal light damage impact CEP biomarker levels. Invest Ophthalmol Vis Sci 50:E-Abstract 681.
80. Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, Krueger DS, Kapin MA, Romano C (2010) Agonists at the serotonin receptor (5HT1A) protect the retina from severe photooxidative stress. Invest Ophthalmol Vis Sci 52:2118-2126.
81. Collier R, Wang Y, Martin E, Ornberg R, Rhoades KL, Romano C (2011) Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci 52(11):8108-8116.
82. Imamura Y, Noda S, Hashizume K, Shinoda K, Yamaguchi M, Uchiyama S, Shimizu T, Mizushima Y, Shirasawa T, Tsubota K (2006) Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci USA 103(30):11282-11287.
83. Justilien V, Pang J, Renganathan K, Zhan X, Crabb JW, Kim SR, Sparrow JR, Hauswirth WW, Lewin AS (2007) SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci 48:4407-4420.
84. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG, Perez VL (2008) Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 14:194-198.
85. Ebrahem Q, Renganathan K, Sears J, Vasanji A, Gu X, Lu L, Salomon RG, Crabb JW, Anand-Apte B (2006) Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization:implications for age-related macular degeneration. Proc Natl Acad Sci USA 103(36):13480-13484.
86. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467(7318):972-976.
87. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C (2008) TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213(3-4):205-224.
88. Sparrow JR, Boulton M (2005) RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 80(5):595-606.
89. Bazan H, Bazan N, Feeney-Burns L, Berman E (1990) Lipids in human lipofuscin-enriched subcellular fractions of two age populations. Comparison with rod outer segments and neural retina. Invest Ophthalmol Vis Sci 31(8):1433-1443.
90. Eldred GE, Lasky MR (1993) Retinal age pigments generated by self-assembling lysosomotropic detergents. Nature 361(6414):724-726.
91. Sakai N, Decatur J, Nakanishi K, Eldred GE (1996) Ocular age pigment "A2-E": an unprecedented pyridinium bisretinoid. J Am Chem Soc 118(6):1559-1560.
92. Sparrow JR (2007) RPE lipofuscin: formation, properties, and relevance to retinal degeneration. In: Tombran-Tink J, Barnstable CJ (eds) Retinal degenerations: biology, diagnostics and therapeutics. Human Press, Totowa, pp 213-236.
93. Kim SR, Jang YP, Jockusch S, Fishkin NE, Turro NJ, Sparrow JR (2007) The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proc Natl Acad Sci USA 104(49):19273-19278.
94. Wu Y, Yanase E, Feng X, Siegel MM, Sparrow JR (2010) Structural characterization of bisretinoid A2E photocleavage products and implications for age-related macular degeneration. Proc Natl Acad Sci USA 107(16):7275-7280.
95. Salomon RG, Sha W, Brame C, Kaur K, Subbanagounder G, O'Neil J, Hoff HF, Roberts LJ II (1999) Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J Biol Chem 274(29):20271-20280.
96. Iyer RS, Ghosh S, Salomon RG (1989) Levuglandin E2 crosslinks proteins. Prostaglandins 37(4):471-480.
97. Murthi KK, Friedman LR, Oleinick NL, Salomon RG (1993) Formation of DNA-protein cross-links in mammalian cells by levuglandin E2. Biochemistry 32(15):4090-4097.
98. Fishkin N, Jang YP, Itagaki Y, Sparrow JR, Nakanishi K (2003) A2-rhodopsin: a new fluorophore isolated from photoreceptor outer segments. Org Biomol Chem 1(7):1101-1105.
99. Holz F, Bellman C, Staudt S, Schütt F, Völcker H (2001) Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 42(5):1051-1056.
100. Bird AC (2010) Therapeutic targets in age-related macular disease. J Clin Invest 120(9):3033-3041.
101. Boulton M, Dontsov A, Jarvis-Evans J, Ostrovsky M, Svistunenko D (1993) Lipofuscin is a photoinducible free radical generator. J Photochem Photobiol B 19(3):201-204.
102. Rozanowska M, Jarvis-Evans J, Korytowski W, Boulton ME, Burke JM, Sarna T (1995) Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem 270(32):18825-18830.
103. Gaillard ER, Atherton SJ, Eldred G, Dillon J (1995) Photophysical studies on human retinal lipofuscin. Photochem Photobiol 61(5):448-453.
104. Sparrow JR, Zhou J, Ben-Shabat S, Vollmer H, Itagaki Y, Nakanishi K (2002) Involvement of oxidative mechanisms in blue light induced damage to A2E-laden RPE. Invest Ophthalmol Vis Sci 43:1222-1227.
105. Boulton M, Rozanowska M, Rozanowski B, Wess T (2004) The photoreactivity of ocular lipofuscin. Photochem Photobiol Sci 3(8):759-764.
106. Jang YP, Matsuda H, Itagaki Y, Nakanishi K, Sparrow JR (2005) Characterization of peroxy-A2E and furan-A2E photooxidation products and detection in human and mouse retinal pigment epithelial cell lipofuscin. J Biol Chem 280(48):39732-39739.
107. Davies S, Elliott MH, Floor E, Truscott TG, Zareba M, Sarna T, Shamsi FA, Boulton ME (2001) Photocytotoxicity of lipofuscin in human retinal pigment epithelial cells. Free Radic Biol Med 31(2):256-265.
108. Schütt F, Davies S, Kopitz J, Holz F, Boulton M (2000) Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 41(8):2303-2308.
109. Sparrow JR, Nakanishi K, Parish CA (2000) The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 41(7):1981-1989.
110. Sparrow JR, Cai B (2001) Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2. Invest Ophthalmol Vis Sci 42(6):1356-1362.
111. Zhou J, Jang YP, Kim SR, Sparrow JR (2006) Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci 103(44):16182-16187.
112. Zhou J, Cai B, Jang YP, Pachydaki S, Schmidt AM, Sparrow JR (2005) Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res 80(4):567-580.
113. Shiose S, Chen Y, Okano K, Roy S, Kohno H, Tang J, Pearlman E, Maeda T, Palczewski K, Maeda A (2011) Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice. J Biol Chem 286:15543-15555.
114. Zarbin MA, Rosenfeld PJ (2010) Pathway-based therapies for age-related macular degeneration:an integrated survey of emerging treatment alternatives. Retina 30(9):1350-1367.
115. Li W, Laird JM, Lu L, Roychowdhury S, Nagy LE, Zhou R, Crabb JW, Salomon RG (2009) Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts. Free Radic Biol Med 47(11):1539-1552.
116. Guichardant M, Taibi-Tronche P, Fay LB, Lagarde M (1998) Covalent modifications of aminophospholipids by 4-hydroxynonenal. Free Radic Biol Med 25(9):1049-1056.
117. Zemski Berry KA, Murphy RC (2007) Characterization of acrolein-glycerophosphoethanolamine lipid adducts using electrospray mass spectrometry. Chem Res Toxicol 20(9):1342-1351.
118. Salomon RG, Batyreva E, Kaur K, Sprecher DL, Schreiber MJ, Crabb JW, Penn MS, DiCorletoe AM, Hazen SL, Podrez EA (2000) Isolevuglandin-protein adducts in humans:products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 1485(2-3):225-235.
119. Uchida K (1999) Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med 9(5):109-113.
120. Xu G, Liu Y, Sayre LM (2000) Polyclonal antibodies to a fluorescent 4-hydroxy-2-nonenal (HNE)-derived lysine-lysine cross-link: characterization and application to HNE-treated protein and in vitro oxidized low-density lipoprotein. Chem Res Toxicol 13(5):406-413.
121. Lau LI, Liu CJ, Wei YH (2010) Increase of 8-hydroxy-2 ¢ -deoxyguanosine in aqueous humor of patients with exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 51(11):5486-5490.
122. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BH, Oppermann M (2008) Systemic complement activation in age-related macular degeneration. PLoS One 3(7):e2593.
123. Huang SJ, Costa DL, Gross NE, Yannuzzi LA (2003) Peripheral drusen in membranoproliferative glomerulonephritis type II. Retina 23(3):429-431.
124. Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Muhlradt PF, Schieffer B (2010) Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood 115(12):2543-2552.